Varicella Vaccine (Chickenpox Vaccine)
Treatment for Varicella And Herpes Zoster
Typical Dosage: 0.5 mL SC, 2 doses (12-15 months, 4-6 years)
Effectiveness
90%
Safety Score
85%
Clinical Trials
188
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
85
DangerousModerateSafe
Treatment Details
Dosage Range
0.5 mL SC, 2 doses (12-15 months, 4-6 years)
Time to Effect
2-4 weeks after first dose
Treatment Duration
Two-dose series, lifelong protection
Evidence Quality
HIGHNumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100000(Treat 100000 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$100
Side Effect Mgmt:$5
Total Annual:$8.1
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$45,000/QALY
QALYs Gained
0.004
Prescription Access Economics
Physician Visit Cost
$5/year
Time Cost
$1/year
Travel + wait time
Insurance Admin Cost
$0.4/year
Prior auth, claims
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWActive Clinical Trials
4 active trials recruiting for Varicella Vaccine (Chickenpox Vaccine) in Varicella And Herpes Zoster
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children
NCT07473427NOT YET RECRUITINGPHASE3
300 participants
INTERVENTIONAL
Hanoi, Vietnam
Started: Jun 15, 2026
Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination
NCT05422508RECRUITINGPHASE2
230 participants
INTERVENTIONAL
Ansan, South Korea
Started: Jul 5, 2022
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
NCT07054099RECRUITINGPHASE3
474 participants
INTERVENTIONAL
Khon Kaen, Thailand
Started: Mar 17, 2026
An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine
NCT06484686ENROLLING BY INVITATIONPHASE4
414 participants
INTERVENTIONAL
Zhengzhou, China
Started: Sep 16, 2024
Completed Clinical Trials
10 completed trials for Varicella Vaccine (Chickenpox Vaccine) in Varicella And Herpes Zoster
A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years
NCT06592456COMPLETEDPHASE3
1.2K participants
INTERVENTIONAL
Huaian, China
Started: Jul 21, 2019
Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
NCT03843632COMPLETEDPHASE3
150 participants
INTERVENTIONAL
Kazan', Russia +4 more
Started: Mar 1, 2019
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines
NCT06314724COMPLETEDPHASE3
642 participants
INTERVENTIONAL
Pasay, Philippines +1 more
Started: Feb 29, 2024
Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age
NCT03114943COMPLETEDPHASE3
516 participants
INTERVENTIONAL
Dasmariñas, Philippines
Started: Jul 14, 2016
Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)
NCT06987942COMPLETEDPHASE4
899 participants
INTERVENTIONAL
Nanjing, China
Started: Sep 21, 2024
The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age
NCT03114982COMPLETEDPHASE2
152 participants
INTERVENTIONAL
Muntinlupa City, Philippines
Started: May 1, 2016
Study on Booster Immunization With Varicella Vaccine at Different Intervals
NCT06994052COMPLETEDPHASE4
412 participants
INTERVENTIONAL
Nanjing, China
Started: Sep 21, 2024
Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults
NCT02367638COMPLETEDPHASE1
39 participants
INTERVENTIONAL
Started: Mar 1, 2015
Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)
NCT00496327COMPLETEDPHASE3
100 participants
INTERVENTIONAL
Started: Jun 22, 2005
T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
NCT01911065COMPLETEDPHASE4
54 participants
INTERVENTIONAL
Stanford, United States
Started: Sep 1, 2010
Showing 20 of 198 total trials